Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pharmacokinetics of BC-3781 in the pulmonary epithelial lining fluid, skeletal muscle tissue, subcutaneous adipose tissue and in plasma of Healthy Subjects

Trial Profile

Pharmacokinetics of BC-3781 in the pulmonary epithelial lining fluid, skeletal muscle tissue, subcutaneous adipose tissue and in plasma of Healthy Subjects

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 01 Apr 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lefamulin (Primary)
  • Indications Bacterial infections; Bone and joint infections; Community-acquired pneumonia; Nosocomial pneumonia; Osteomyelitis; Sexually transmitted infections; Skin and soft tissue infections
  • Focus Pharmacokinetics
  • Sponsors Nabriva Therapeutics
  • Most Recent Events

    • 01 Apr 2019 Results of population PK model to predict the ELF penetration ratio of lefamulin after IV or oral administration in the fed and fasted state using data from NAB-BC3781-1107 and NAB-BC3781-1005 studies, published in the Journal of Antimicrobial Chemotherapy
    • 07 Jan 2016 Results published in the Journal of Antimicrobial Chemotherapy
    • 16 Sep 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top